Double Helix Development

November 13 2009

Healthcare specialist Double Helix Development has expanded its UK team with the appointments of Sahil Kirpekar and Enrico de Nigris, and hired Mike Rizzo as a new member of its US Consulting office. Kirpekar is a registered medical practitioner who previously worked as a medical doctor in the UK and India. His business experience extends across global pharmaceutical projects for ‘Big Pharma’ and with the World Health Organization in Geneva, where he undertook research on access to HIV medicines. Most recently, de Nigris worked as Outcomes Research Manager at Pfizer, where he provided technical and strategic health economics support to global products in the areas of smoking cessation, diabetes, pulmonary arterial hypertension and VTE. Prior to this, he was a health economist at the National Collaborating Centre for Acute Care and a Research Associate in Health Economics at ScHARR. Rizzo joins the firm from Campbell Alliance’s managed markets practice, where he led client engagements in stakeholder and access risk assessment, value proposition development and messaging. He has extensive experience in assessing the impact of payers, physicians, patients and intermediaries on pricing, access, and reimbursement for small molecule and specialty products in the US market. During his career, he has worked with Charles River Associates’ pharmaceuticals practice, the Pharmaceutical Research and Manufacturers Association (PhRMA), the Lombardi Cancer Research Center at Georgetown University, and The Institute for Genomic Research (TIGR). Double Helix Development, which has US offices in New York and Fort Washington, near Philadelphia and a UK base in London, is online at www.doublehelixdevelopment.com . Printer-friendly version of this article. Email this article to a friend. Register for News emails